Comparing the efficacy and safety of cyclophosphamide and ritux-imab in idiopathic membranous nephropathy
10.12092/j.issn.1009-2501.2025.05.009
- VernacularTitle:对比环磷酰胺和利妥昔单抗在特发性膜性肾病中的疗效及安全性分析
- Author:
Shan WU
1
;
Qi YU
;
Qin YANG
;
Wenjing WANG
;
Yangyang ZHANG
;
Yan LIU
;
Yanlang YANG
Author Information
1. 皖南医学院第一附属医院弋矶山医院肾脏内科,芜湖 241000,安徽
- Publication Type:Journal Article
- Keywords:
membranous nephropathy;
ritux-imab;
cyclophosphamide;
eGFR
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2025;30(5):657-664
- CountryChina
- Language:Chinese
-
Abstract:
AIM:To explore the efficacy and safe-ty of two drugs in diagnosed idiopathic membra-nous nephropathy(IMN).METHODS:A retrospec-tive study was conducted on 113 patients diag-nosed with IMN by renal biopsy or PLA2R antibody positive at the department of nephrology,yijishan hospital,wannan medical college from november 2019 to July 2024,of whom 55 received cyclophos-phamide treatment and 58 received rituximab treatment,and follow-up was ≥6 months.RESULTS:At 6 months,38 patients(69.09％)in the cyclophos-phamide treatment group and 36 patients(62.07％)in the rituximab treatment group had achieved a combined response(complete or partial response).At 12 and 18 months,there was no statistical differ-ence in the combined response rate between the two groups(70.83％vs.83.87％,P=0.186 and 73.68％vs.73.68％,P=1.000),but at 12 months,the combined response rate in the rituximab group was higher than that in the cyclophosphamide group.In IMN patients with eGFR＜60 mL/(min·1.73 m2),rituximab significantly improved renal function(P=0.008).Over the entire follow-up peri-od,the total number of adverse events was higher in the cyclophosphamide group than in the ritux-imab group(57 vs..45),and the incidence of non-serious adverse events was higher than in the ritux-imab group(P=0.039).CONCLUSION:The efficacy of rituximab in the treatment of IMN is not inferior to that of cyclophosphamide,and it has better safety.Rituximab improved renal function better than cy-clophosphamide in patients with eGFR＜60 mL/(min·1.73 m2)IMN.
